Ovarian malignant tumor is one of the common malignant tumors of female reproductive organs, and its incidence rate ranks third only after cervical cancer and endometrial cancer. However, the mortality of ovarian epithelial cancer accounts for the first place in all kinds of gynecological tumors, posing a serious threat to women's lives. It is therefore critical to ensure that the ADC releases the drug while it is still extracellular. To achieve this goal, Tagworks has designed a smart ADC that binds to cancer receptors when injected into the body, and after 1-2 days, the cells are enriched with ADCs. Robillard said: "Our innovation is that we use a second component that can 'click release' chemotherapy drugs from the ADC. The result is a large number of chemotherapy drugs that release quickly and attack the tumor. This method is promising for a variety of treatments. "
https://www.creative-biolabs.com/adc/services.htm